DMCC SPECIALITY CHEMICALS LIMITED has informed the Exchange regarding Change in Director(s) of the company.
DMCC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
DMCC Speciality Chemicals' board met on August 7, 2025 and approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone net sales jumped to Rs. 12,702.32 lakhs from Rs. 8,531.81 lakhs in the same quarter last year, a growth of about 49%. Net profit surged sharply to Rs. 775.31 lakhs (vs. Rs. 138.58 lakhs in Q1 FY25), with EPS rising to Rs. 3.11 from Rs. 0.56. The board also re-appointed Dr. Janaki Ashwin Patwardhan as a Non-Executive Independent Director for a second 5-year term beginning May 21, 2026, subject to shareholder approval. Statutory auditors Rahul Gautam Divan & Associates issued an unmodified limited review report on the results.
A strong quarter with revenues up nearly 49% and profits up over 5x year-on-year is a positive signal for shareholders, likely to be viewed favorably by the market. The re-appointment of the existing independent director signals board continuity with no governance concerns flagged.